A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Atrial Fibrillation
In brief
This was a randomized, placebo-controlled, investigator- and participant-blinded study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of HSY244 in participants with atrial fibrillation (AF), with and without heart failure (HF).
Key facts
- Study ID
- NCT04582409
- Run by
- Novartis Pharmaceuticals
- People needed
- 13
- Starts
- 2020-11-30
- Expected to finish
- 2022-07-11
- Last updated by the study team
- 2024-06-20
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Boston, Massachusetts, United States
- Novartis Investigative Site — Lansing, Michigan, United States
- Novartis Investigative Site — Bad Oeynhausen, Germany
- Novartis Investigative Site — Frankfurt, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.